Open an account

Whitehawk Therapeutics

WHWK · NASDAQ

$3.19+$0.18 (+5.98%)TodayMarket closed ·
Prev close $3.01

About WHWK

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 23 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.

Employees
23
Headquarters
Morristown, New Jersey
Listed
Jun 26, 2018
Sector
Health Care
Industry
Biotechnology
Website
ir.whitehawktx.com

WHWK key statistics

Market cap
207.07M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
320.72K
Volume
417.76K
Open price
$3.02
High today
$3.24
Low today
$3.02
52 Week high
$5.50
52 Week low
$1.97

Whitehawk Therapeutics (WHWK) at a glance

Whitehawk Therapeutics (WHWK) last traded at $3.19, with a market cap of 207.07M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.02 and $3.24. The current price is 5.6% above the day's low and 1.5% below its high.

Volume so far is 417.76K shares, above the average of 320.72K shares a day.

Over the past year Whitehawk Therapeutics has ranged from $1.97 to $5.50, and now sits 35% of the way up that range.

Whitehawk Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.20 per share against an estimate of -$0.3018.

The average analyst price target is $7.87, 146.7% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $7.87
Low
$4.04
Now
$3.19
High
$10.50

WHWK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 17.1% on average.

  1. Q3 FY24: reported -$0.46 per share against an estimate of -$0.4667
  2. Q4 FY24: reported -$0.67 per share against an estimate of -$0.2244
  3. Q1 FY25: reported -$0.37 per share against an estimate of -$0.4692
  4. Q2 FY25: reported -$0.76 per share against an estimate of $0.5032
  5. Q3 FY25: reported -$0.26 per share against an estimate of $0.068
  6. Q4 FY25: reported -$0.34 per share against an estimate of -$0.1571
  7. Q1 FY26: reported -$0.32 per share against an estimate of -$0.3641
  8. Q2 FY26: reported -$0.20 per share against an estimate of -$0.3018

WHWK news

  • Press releasePRNewswire

    Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

  • Press releasePRNewswire

    Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

  • Press releasePRNewswire

    Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

  • Press releasePRNewswire

    Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

  • Press releasePRNewswire

    Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

  • Press releaseBusiness Wire

    Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

  • Press releasePRNewswire

    Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

  • Press releasePRNewswire

    Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Similar companies

Companies in the same industry as Whitehawk Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.